IP Library Granted Patent US 12,414,925
Granted Patent B2
US 12,414,925 · App. 17/418,418 · Granted Sep 16, 2025

External composition

Inventors: Daisaku Nagaike (Dalton, GA); Tsuyoshi Igaue (Dalton, GA)
Assignee: Kobayashi Pharmaceutical Co., Ltd.
A61K31/167A61K9/0014A61K9/06A61K9/7007A61K47/10A61K47/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,414,925
App. No.
17/418,418
Granted
Sep 16, 2025
Kind
B2
Abstract

The present disclosure provides an external composition containing lidocaine, a cool feeling agent, and vanillyl butyl ether.

Claims (37)

1. An external composition comprising lidocaine, a cool feeling agent, and vanillyl butyl ether, wherein

the external composition has 2% or more by weight of lidocaine,

the cool feeling agent comprises I-menthol,

the amount of I-menthol is 62.5 to 100 parts by weight based on 100 parts by weight of lidocaine,

the amount of vanillyl butyl ether is 4 to 6 parts by weight based on 100 parts by weight of I-menthol,

the composition comprises 50 to 90% by weight of water, and

the composition comprises a gel substrate.

2. The external composition according to claim 1 , wherein the cool feeling agent is I-menthol.

3. The external composition according to claim 1 , comprising 0.01 to 10% by weight of the cool feeling agent.

4. The external composition according to claim 1 , comprising 0.005 to 1.0% by weight of vanillyl butyl ether.

5. The external composition according to claim 1 , wherein the ratio of the cool feeling agent to vanillyl butyl ether is 1:0.001 to 1:0.4.

6. The external composition according to claim 1 , comprising 2 to 10% by weight of lidocaine.

7. The external composition according to claim 1 , comprising aluminum hydroxide, sodium polyacrylate, polyacrylic acid and polyvinyl alcohol as the gel substrate.

8. A patch comprising a composition layer comprising the external composition according to claim 1 , the composition layer being stacked on a support.

9. The patch according to claim 8 , wherein the support is a nonwoven fabric.

10. The patch according to claim 8 , wherein the composition layer has a maximum thickness of 0.5 mm or more.

11. An external composition comprising lidocaine, a cool feeling agent, and vanillyl butyl ether, wherein

the cool feeling agent has 2.5 to 10% by weight of I-menthol,

the amount of I-menthol is 62.5 to 100 parts by weight based on 100 parts by weight of lidocaine,

the amount of vanillyl butyl ether is 4 to 6 parts by weight based on 100 parts by weight of I-menthol,

the composition comprises 50 to 90% by weight of water, and

the composition comprises a gel substrate.

12. An external composition comprising lidocaine,

a cool feeling agent,

vanillyl butyl ether,

less than 0.05% by weight methylparaben, and

less than 0.02% by weight propylparaben, wherein

the cool feeling agent comprises I-menthol,

the amount of I-menthol is 62.5 to 100 parts by weight based on 100 parts by weight of lidocaine,

the amount of vanillyl butyl ether is 4 to 6 parts by weight based on 100 parts by weight of I-menthol,

the composition comprises 50 to 90% by weight of water, and

the composition comprises a gel substrate.

13. The external composition according to claim 1 , comprising 0.01 to 5% by weight of the cool feeling agent.

14. The external composition according to claim 1 , comprising 0.01 to 0.5% by weight of vanillyl butyl ether.

15. The external composition according to claim 1 , wherein the ratio of the cool feeling agent to vanillyl butyl ether is 1:0.001 to 1:0.2.

16. The external composition according to claim 1 , wherein the ratio of the cool feeling agent to vanillyl butyl ether is 1:0.001 to 1:0.1.

17. The external composition according to claim 1 , wherein the ratio of the cool feeling agent to vanillyl butyl ether is 1:0.01 to 1:0.1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2021
From: NAGAIKE, DAISAKU; IGAUE, TSUYOSHI
To: KOBAYASHI PHARMACEUTICAL CO., LTD.
Reel/Frame 056674/0872 →
Continuity (2)
Provisional Application 62785358 · Dec 27, 2018
Related Publication 20220047533A1 · Feb 17, 2022
References Cited (16)
US 6328982B1 · Shiroyama · 2001 [cited by examiner]
US 10307380B1 · Mantelle · 2019 [cited by applicant]
US 20170087199A1 · Patron et al. · 2017 [cited by applicant]
US 20180057447A1 · Itoh et al. · 2018 [cited by applicant]
EP 0988852A2 · 2000 [cited by applicant]
EP 1197205A2 · 2002 [cited by applicant]
JP H1072312 · 1998 [cited by examiner]
JP 2004210668A · 2004 [cited by examiner]
JP 2013136532A · 2013 [cited by applicant]
JP 2014152172A · 2014 [cited by applicant]
JP 2018083069A · 2018 [cited by examiner]
WO 2016153011A1 · 2016 [cited by applicant]
JPH1072312, text (Year: 2024). [cited by examiner]
JP2018-083069 (Year 2018). [cited by examiner]
International Search Report issued in corresponding International Patent Application No. PCT/IB2019/061381 dated Mar. 31, 2020. [cited by applicant]
Written Opinion issued in corresponding International Patent Application No. PCT/IB2019/061381 dated Mar. 31, 2020. [cited by applicant]